573 related articles for article (PubMed ID: 21486975)
61. Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls: Results to Month 12 From a Randomized Trial.
Lin L; Parra MM; Sierra VY; Cespedes AS; Granados MA; Luque A; Damaso S; Castrejon Alba MM; Romano-Mazzotti L; Struyf F
Pediatr Infect Dis J; 2018 Apr; 37(4):e93-e102. PubMed ID: 29424799
[TBL] [Abstract][Full Text] [Related]
62. Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals.
Widdice LE; Unger ER; Panicker G; Hoagland R; Callahan ST; Jackson LA; Berry AA; Kotloff K; Frey SE; Harrison CJ; Pahud BA; Edwards KM; Mulligan MJ; Sudman J; Bernstein DI
Vaccine; 2018 Feb; 36(6):881-889. PubMed ID: 29306506
[TBL] [Abstract][Full Text] [Related]
63. Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine.
Senders S; Bhuyan P; Jiang Q; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Ginis J; Perez JL
Pediatr Infect Dis J; 2016 May; 35(5):548-54. PubMed ID: 26835974
[TBL] [Abstract][Full Text] [Related]
64. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.
Leroux-Roels G; Haelterman E; Maes C; Levy J; De Boever F; Licini L; David MP; Dobbelaere K; Descamps D
Clin Vaccine Immunol; 2011 Sep; 18(9):1510-8. PubMed ID: 21734063
[TBL] [Abstract][Full Text] [Related]
65. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV
Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886
[TBL] [Abstract][Full Text] [Related]
66. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
67. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
Luxembourg A; Brown D; Bouchard C; Giuliano AR; Iversen OE; Joura EA; Penny ME; Restrepo JA; Romaguera J; Maansson R; Moeller E; Ritter M; Chen J
Hum Vaccin Immunother; 2015; 11(6):1313-22. PubMed ID: 25912208
[TBL] [Abstract][Full Text] [Related]
68. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.
Zhu F; Li J; Hu Y; Zhang X; Yang X; Zhao H; Wang J; Yang J; Xia G; Dai Q; Tang H; Suryakiran P; Datta SK; Descamps D; Bi D; Struyf F
Hum Vaccin Immunother; 2014; 10(7):1795-806. PubMed ID: 25424785
[TBL] [Abstract][Full Text] [Related]
69. Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
Shu Y; Yu Y; Ji Y; Zhang L; Li Y; Qin H; Huang Z; Ou Z; Huang M; Shen Q; Li Z; Hu M; Li C; Zhang G; Zhang J
Vaccine; 2022 Nov; 40(48):6947-6955. PubMed ID: 36283897
[TBL] [Abstract][Full Text] [Related]
70. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
71. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong.
Ngan HY; Cheung AN; Tam KF; Chan KK; Tang HW; Bi D; Descamps D; Bock HL
Hong Kong Med J; 2010 Jun; 16(3):171-9. PubMed ID: 20519752
[TBL] [Abstract][Full Text] [Related]
72. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial.
Wheeler CM; Harvey BM; Pichichero ME; Simon MW; Combs SP; Blatter MM; Marshall GS; Catteau G; Dobbelaere K; Descamps D; Dubin G; Schuind A
Pediatr Infect Dis J; 2011 Dec; 30(12):e225-34. PubMed ID: 21817954
[TBL] [Abstract][Full Text] [Related]
73. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
74. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial.
Baisley K; Kemp TJ; Kreimer AR; Basu P; Changalucha J; Hildesheim A; Porras C; Whitworth H; Herrero R; Lacey CJ; Schiller JT; Lucas E; Mutani P; Dillner J; Indangasi J; Muwonge R; Hayes RJ; Pinto LA; Watson-Jones D
Lancet Glob Health; 2022 Oct; 10(10):e1485-e1493. PubMed ID: 36113532
[TBL] [Abstract][Full Text] [Related]
75. Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals.
Russell K; Dunne EF; Kemper AR; Dolor RJ; Unger ER; Panicker G; Markowitz LE; Walter EB
Vaccine; 2015 Apr; 33(16):1953-8. PubMed ID: 25744229
[TBL] [Abstract][Full Text] [Related]
76. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
Mugo NR; Eckert L; Magaret AS; Cheng A; Mwaniki L; Ngure K; Celum C; Baeten JM; Galloway DA; Wamalwa D; Wald A
Vaccine; 2018 Nov; 36(46):7025-7032. PubMed ID: 30297124
[TBL] [Abstract][Full Text] [Related]
77. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial.
Thiem VD; Quang ND; Tuan NH; Cheon K; Gallagher N; Luxembourg A; Group T; Badshah C
Hum Vaccin Immunother; 2021 Jul; 17(7):1980-1985. PubMed ID: 33844623
[TBL] [Abstract][Full Text] [Related]
78. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G;
Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700
[TBL] [Abstract][Full Text] [Related]
79. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
Toft L; Storgaard M; Müller M; Sehr P; Bonde J; Tolstrup M; Østergaard L; Søgaard OS
J Infect Dis; 2014 Apr; 209(8):1165-73. PubMed ID: 24273179
[TBL] [Abstract][Full Text] [Related]
80. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
